These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 8913395)

  • 21. FDA sets hierarchy for biosimilars evidence.
    Ratner M
    Nat Biotechnol; 2014 Jul; 32(7):609. PubMed ID: 25004221
    [No Abstract]   [Full Text] [Related]  

  • 22. Science and regulation. FDA's approach to regulation of products of nanotechnology.
    Hamburg MA
    Science; 2012 Apr; 336(6079):299-300. PubMed ID: 22517845
    [No Abstract]   [Full Text] [Related]  

  • 23. Legislative reform proposals.
    Bruderle TP
    Am J Health Syst Pharm; 1996 Sep; 53(17):2083-7. PubMed ID: 8870897
    [No Abstract]   [Full Text] [Related]  

  • 24. Regulatory watch: Innovative drug availability in China.
    Shao L; Xu L; Li Q; Chakravarthy R; Yang Z; Kaitin KI
    Nat Rev Drug Discov; 2016 Nov; 15(11):739-740. PubMed ID: 27765941
    [No Abstract]   [Full Text] [Related]  

  • 25. Losing deference in the FDA's second century: judicial review, politics, and a diminished legacy of expertise.
    O'Reilly JT
    Cornell Law Rev; 2008 Jul; 93(5):939-80. PubMed ID: 18618965
    [No Abstract]   [Full Text] [Related]  

  • 26. FDA's expanding postmarket authority to monitor and publicize food and consumer health product risks: the need for procedural safeguards to reduce "transparency" policy harms in the post-9/11 regulatory environment.
    Roller ST; Pippins RR; Ngai JW
    Food Drug Law J; 2009; 64(3):577-98. PubMed ID: 19999646
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The FDA Export Reform and Enhancement Act of 1996: the FDA's new extraterritorial authority over labeling and promotional practices.
    Helmanis AM
    Food Drug Law J; 1996; 51(4):631-5. PubMed ID: 11797732
    [No Abstract]   [Full Text] [Related]  

  • 28. Silencing the FDA's Voice - Drug Information on Trial.
    Watson T; Robertson C
    N Engl J Med; 2023 Dec; 389(25):2312-2314. PubMed ID: 38108407
    [No Abstract]   [Full Text] [Related]  

  • 29. Second thoughts: do the FDA's responses to a fatal drug trial and the AIDS activist community's doubts about early access to drugs hint at a shift in basic FDA policy?
    Lovell MC
    Food Drug Law J; 1996; 51(2):273-94. PubMed ID: 11820202
    [No Abstract]   [Full Text] [Related]  

  • 30. The Food and Drug Administration and patent law at a crossroads: the listing of polymorph patents as a barrier to generic drug entry.
    Srivastava D
    Food Drug Law J; 2004; 59(2):339-54. PubMed ID: 15298015
    [No Abstract]   [Full Text] [Related]  

  • 31. Recent developments in health law. Administrative law v. constitutional law: the correct decision on FDA's treatment of Plan B.
    Shachar C
    J Law Med Ethics; 2009; 37(3):523-7. PubMed ID: 19723264
    [No Abstract]   [Full Text] [Related]  

  • 32. Facilitating Both Evidence and Access: Improving FDA's Accelerated Approval and Expanded Access Pathways.
    Lynch HF; Bateman-House A
    J Law Med Ethics; 2020 Jun; 48(2):365-372. PubMed ID: 32631197
    [No Abstract]   [Full Text] [Related]  

  • 33. Gabbing about gabapentin.
    Nat Rev Drug Discov; 2003 Apr; 2(4):254. PubMed ID: 12680367
    [No Abstract]   [Full Text] [Related]  

  • 34. Food and Drug Administration Review and Action on Over-the-Counter Time and Extent Applications. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2016 Nov; 81(226):84465-77. PubMed ID: 27906534
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The FDA and "privatization"--the drug approval process.
    Rutherford EM
    Food Drug Law J; 1995; 50 Spec():203-25. PubMed ID: 10343044
    [No Abstract]   [Full Text] [Related]  

  • 36. Lawsuits anticipated on generic biologicals front.
    Fox JL
    Nat Biotechnol; 2003 Jul; 21(7):721-2. PubMed ID: 12833078
    [No Abstract]   [Full Text] [Related]  

  • 37. FDA's role in administering the Hatch-Waxman Act.
    Malkin BJ
    Food Drug Law J; 1999; 54(2):211-4. PubMed ID: 11758575
    [No Abstract]   [Full Text] [Related]  

  • 38. Pediatric drug trials. Challenge to FDA's authority may end up giving it more.
    Marshall E
    Science; 2002 May; 296(5569):820-1. PubMed ID: 11988539
    [No Abstract]   [Full Text] [Related]  

  • 39. FDA reform in Congress: FDA's concerns. Food and Drug Administration.
    James JS
    AIDS Treat News; 1996 Apr; (no 245):5-7. PubMed ID: 11363624
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The History and Political Economy of the Hatch-Waxman Amendments.
    Lietzan E
    Seton Hall Law Rev; 2019; 49(1):53-127. PubMed ID: 30557922
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.